Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Pikavation Therapeutics Inc. is navigating the patent process with 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This singular focus suggests a streamlined prosecution strategy where resources are directed toward a specific intellectual property asset. The presence of 1 distinct examiner and 1 distinct art unit indicates that the company's current interactions with the USPTO are centralized, requiring a targeted approach to examiner engagement.
The busiest examiner assigned to the portfolio is ROMERO, KRISTEN WANG, who currently handles 1 pending office action. Since this examiner is responsible for the entirety of the company's pending actions, the prosecution success for this portfolio is currently tied to the specific feedback and requirements of ROMERO, KRISTEN WANG. This lack of examiner variety means the company cannot compare prosecution experiences across different individuals at this stage.
For a practitioner, the concentration in 1 distinct art unit and 1 distinct examiner simplifies the monitoring of deadlines and procedural requirements. However, it also means that any single office action carries significant weight for the overall portfolio health. The company must ensure that its responses are precisely tailored to the expectations of the assigned examiner to maintain progress in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROMERO, KRISTEN WANG | 1 | 69.8% | +30.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18843508 | PI3Ka INHIBITORS | ROMERO, KRISTEN WANG | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18843508 | PI3Ka INHIBITORS | ROMERO, KRISTEN WANG | 1624 | §112 | Non-Final OA | — | Pending | Sep 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPikavation Therapeutics Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Kristen Wang Romero has the most, with 1 of Pikavation Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.